Literature DB >> 32350808

Primary Parotid Merkel Type Small Cell Neuroendocrine Carcinoma with Oligometastasis to the Brain and Adrenal Gland: Case Report and Review of Literature.

Sympascho Young1, Justin Oh2, Hussam Bukhari3, Tony Ng3, Nichole Chau4, Eric Tran2.   

Abstract

Oligometastatic disease is a hypothesized intermediate stage of disease between localized and widespread metastatic cancer. Localized treatment of oligometastatic lesions may offer survival advantages in addition to systemic treatment. In this case report, we describe a patient who presented with small cell neuroendocrine carcinoma "Merkel type" (SNECM) of the parotid gland which had metastasized to the brain and adrenal gland. He was treated with chemotherapy followed by stereotactic radiotherapy and volumetric modulated arc therapy for oligometastasis. He maintains good functional status with low burden of disease at 20-months after diagnosis. SNECM is a rare and aggressive parotid cancer with immunohistochemical and morphologic similarities to Merkel cell carcinoma (MCC). There are only 44 cases of parotid SNECM in the English literature. This is the first case to describe management of oligometastatic SNECM and we review literature on management of both SNECM and metastatic MCC.

Entities:  

Keywords:  Brain metastasis; Case report; Merkel cell carcinoma; Merkel cell type; Oligometastasis; Parotid gland; Small cell neuroendocrine carcinoma; Stereotactic radiotherapy

Year:  2020        PMID: 32350808      PMCID: PMC8010043          DOI: 10.1007/s12105-020-01164-w

Source DB:  PubMed          Journal:  Head Neck Pathol        ISSN: 1936-055X


  34 in total

1.  Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial.

Authors:  Hidefumi Aoyama; Hiroki Shirato; Masao Tago; Keiichi Nakagawa; Tatsuya Toyoda; Kazuo Hatano; Masahiro Kenjyo; Natsuo Oya; Saeko Hirota; Hiroki Shioura; Etsuo Kunieda; Taisuke Inomata; Kazushige Hayakawa; Norio Katoh; Gen Kobashi
Journal:  JAMA       Date:  2006-06-07       Impact factor: 56.272

2.  Spontaneous regression of advanced merkel-cell-like small cell carcinoma of the parotid gland.

Authors:  D C Mulder; A J W P Rosenberg; P W Storm-Bogaard; R Koole
Journal:  Br J Oral Maxillofac Surg       Date:  2009-07-19       Impact factor: 1.651

3.  Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial.

Authors:  Howard L Kaufman; Jeffery Russell; Omid Hamid; Shailender Bhatia; Patrick Terheyden; Sandra P D'Angelo; Kent C Shih; Céleste Lebbé; Gerald P Linette; Michele Milella; Isaac Brownell; Karl D Lewis; Jochen H Lorch; Kevin Chin; Lisa Mahnke; Anja von Heydebreck; Jean-Marie Cuillerot; Paul Nghiem
Journal:  Lancet Oncol       Date:  2016-09-01       Impact factor: 41.316

4.  Merkel cell carcinoma and HIV infection.

Authors:  Eric A Engels; Morten Frisch; James J Goedert; Robert J Biggar; Robert W Miller
Journal:  Lancet       Date:  2002-02-09       Impact factor: 79.321

Review 5.  Proceedings of the NASHNP Companion Meeting, March 18th, 2018, Vancouver, BC, Canada: Salivary Neuroendocrine Carcinoma-An Overview of a Rare Disease with an Emphasis on Determining Tumor Origin.

Authors:  Rebecca D Chernock; Eric J Duncavage
Journal:  Head Neck Pathol       Date:  2018-03-20

6.  Primary neuroendocrine small cell undifferentiated carcinoma of the parotid gland.

Authors:  S Jorcano; A Casado; J Berenguer; M Arenas; A Rovirosa; L Colomo
Journal:  Clin Transl Oncol       Date:  2008-05       Impact factor: 3.405

Review 7.  Merkel cell carcinoma.

Authors:  Jürgen C Becker; Andreas Stang; James A DeCaprio; Lorenzo Cerroni; Celeste Lebbé; Michael Veness; Paul Nghiem
Journal:  Nat Rev Dis Primers       Date:  2017-10-26       Impact factor: 52.329

8.  Parotid small cell carcinoma presenting with long-term survival after surgery alone: a case report.

Authors:  Takeharu Kanazawa; Noriyoshi Fukushima; Hidetaka Tanaka; Juntaro Shiba; Hiroshi Nishino; Hiroyuki Mineta; Keiichi Ichimura
Journal:  J Med Case Rep       Date:  2012-12-28

9.  Primary parotid Merkel cell carcinoma: a first imagery and treatment response assessment by 18F-FDG PET.

Authors:  Fabrice Giroulet; Flavian Tabotta; Anastasia Pomoni; John Prior
Journal:  BMJ Case Rep       Date:  2019-03-09

10.  Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after ≥1 year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial.

Authors:  Howard L Kaufman; Jeffery S Russell; Omid Hamid; Shailender Bhatia; Patrick Terheyden; Sandra P D'Angelo; Kent C Shih; Céleste Lebbé; Michele Milella; Isaac Brownell; Karl D Lewis; Jochen H Lorch; Anja von Heydebreck; Meliessa Hennessy; Paul Nghiem
Journal:  J Immunother Cancer       Date:  2018-01-19       Impact factor: 13.751

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.